Latest Breaking News On - Fennec pharmaceuticals - Page 8 : comparemela.com

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH.

United statesRobert andradeLindsay roccoExchange commissionFennec pharmaceuticals incElixir health public relationsCompany expects toClinical oncology groupDrug administrationOregon healthFennec pharmaceuticalsEuropean commission marketing authorizationScience universityFourth quarterCompany expectsAudited full year results

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has.

United statesLindsay roccoRobert andradeOregon healthOffice of communicationsScience universityElixir health public relationsFennec pharmaceuticalsFennec pharmaceuticals incDrug administrationStakeholder engagement staffDrug evaluationEuropean commission marketing authorizationOrphan drug exclusivityPediatric use marketing authorization

Fennec Pharmaceuticals (FENC) Reports FDA Issued Reminder of Non-Substitution of PEDMARK for Pediatric Patients Receiving Cisplatin

Fennec Pharmaceuticals (FENC) Reports FDA Issued Reminder of Non-Substitution of PEDMARK for Pediatric Patients Receiving Cisplatin
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Drug administrationOffice of communicationsFennec pharmaceuticals incFennec pharmaceuticalsStakeholder engagement staffDrug evaluation

Eli Lilly Sounds Off as Early Data Show How Gene Therapy Can Restore Hearing

Eli Lilly said its experimental gene therapy restored hearing in a boy born with profound hearing loss. The results for this experimental treatment come three months after Regeneron Pharmaceuticals reported early but encouraging data for its hearing loss gene therapy.

United statesLilly akouosEli lillyJohn germillerRegeneron pharmaceuticalsFennec pharmaceuticalsAssociation for researchDecibel therapeuticsWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciencesRock health

Robert Andrade Sells 15,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Robert Andrade Sells 15,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesRobert andradeCapital managementHarbert fund advisors incFennec pharmaceuticals company profileFennec pharmaceuticals incNews ratings for fennec pharmaceuticals dailyFennec pharmaceuticalsSecurities exchange commissionQuarter for fennec pharmaceuticalsFennec pharmaceuticals stock performanceBlackrock incSolas capital managementGet free reportExchange commissionPharmaceuticals inc